Login to Your Account

CRT, Merck Serono Ink Deal For Drugs to Block WNT Signal

By Nuala Moran
Staff Writer

Wednesday, August 7, 2013
LONDON – Cancer Research Technology Ltd. (CRT) agreed to its third licensing deal in six weeks, signing up Merck Serono SA to take forward compounds that block the WNT cell-signaling pathway.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription